Wells Fargo & Company Raises GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $97.00

GE HealthCare Technologies (NASDAQ:GEHC) had its target price increased by analysts at Wells Fargo & Company from $95.00 to $97.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 16.62% from the company’s current price.

Other research analysts also recently issued reports about the company. UBS Group downgraded GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $73.00 to $77.00 in a research report on Thursday, January 15th. Morgan Stanley lifted their price target on GE HealthCare Technologies from $80.00 to $85.00 and gave the company an “equal weight” rating in a report on Wednesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of GE HealthCare Technologies in a research report on Monday, December 29th. Jefferies Financial Group raised their price objective on GE HealthCare Technologies from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Stifel Nicolaus set a $98.00 price objective on shares of GE HealthCare Technologies in a research report on Wednesday. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $92.42.

GE HealthCare Technologies Trading Up 0.7%

GEHC stock traded up $0.55 during trading on Thursday, hitting $83.18. 965,178 shares of the company traded hands, compared to its average volume of 3,547,594. The firm has a market capitalization of $37.89 billion, a PE ratio of 17.18, a P/E/G ratio of 2.38 and a beta of 1.08. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.95 and a current ratio of 1.18. The company has a 50-day moving average of $82.68 and a 200-day moving average of $77.47. GE HealthCare Technologies has a 1 year low of $57.65 and a 1 year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, February 4th. The company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.04. GE HealthCare Technologies had a return on equity of 22.52% and a net margin of 10.94%.The firm had revenue of $5.70 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the firm posted $1.45 earnings per share. The business’s revenue was up 7.1% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.950-5.150 EPS. Analysts predict that GE HealthCare Technologies will post 4.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GEHC. New York Life Investment Management LLC increased its holdings in shares of GE HealthCare Technologies by 0.7% in the fourth quarter. New York Life Investment Management LLC now owns 62,287 shares of the company’s stock valued at $5,109,000 after purchasing an additional 454 shares during the period. E Fund Management Hong Kong Co. Ltd. increased its stake in GE HealthCare Technologies by 301.7% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,390 shares of the company’s stock valued at $111,000 after purchasing an additional 1,044 shares during the last quarter. Western Wealth Management LLC grew its holdings in GE HealthCare Technologies by 2.4% in the 4th quarter. Western Wealth Management LLC now owns 5,240 shares of the company’s stock valued at $430,000 after buying an additional 125 shares during the period. Independent Advisor Alliance increased its stake in shares of GE HealthCare Technologies by 1.7% during the 4th quarter. Independent Advisor Alliance now owns 13,497 shares of the company’s stock valued at $1,107,000 after acquiring an additional 229 shares during the last quarter. Finally, Legacy Financial Advisors Inc. boosted its position in shares of GE HealthCare Technologies by 15.7% in the fourth quarter. Legacy Financial Advisors Inc. now owns 13,270 shares of the company’s stock worth $1,088,000 after acquiring an additional 1,804 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies News Roundup

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Q4 results beat consensus — EPS $1.44 vs. ~$1.40 and revenue $5.70B (up ~7% y/y), reflecting strength in Imaging and Pharmaceutical Diagnostics; management provided slides and commentary underscoring growth drivers. GE HealthCare reports fourth quarter and full year 2025 financial results
• Positive Sentiment: FY‑2026 guidance raised and above consensus — company set EPS guidance of $4.95–$5.15 (slightly above Street), which supports upside to estimates and the stock’s re-rating into the mid‑teens P/E range. Reuters: GE HealthCare forecasts 2026 profit above estimates
• Positive Sentiment: Analyst bullishness — BTIG raised its price target to $91 and kept a Buy, signaling analyst confidence in upside from current levels and validating the beat/guidance reaction. StreetInsider: PT Raised to $91 at BTIG
• Positive Sentiment: Regulatory win expands product lineup — FDA clearance and CE mark for the Allia Moveo mobile C‑arm (AI guidance, compact design) supports commercialization and incremental imaging revenue. Zacks: GEHC wins FDA clearance & CE mark for Allia Moveo
• Neutral Sentiment: Earnings call transcript and details available — full management commentary and Q&A (useful for modeling guidance drivers and margin outlook). Seeking Alpha: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Company materials posted — press release, slide deck and conference call recording are available for deeper review of segment trends and FY guidance assumptions. MarketBeat: Earnings report and materials
• Negative Sentiment: Margin pressure and lower profit — net margin declined (tariffs, product mix and investments were cited) and headline profit fell versus prior year despite higher revenue, which could cap near‑term margin expansion. Zacks: Net margin falls WSJ: Posts lower profit despite higher revenue

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.